Biodexa shares surge 112.54% intraday after launching global early/patient-specific access program for eRapa with Tanner Pharma.

Biodexa surged 112.54% intraday, following the announcement of a global early/patient-specific access program for eRapa with Tanner Pharma, providing FAP patients access to the investigational oral rapamycin capsule. Biodexa is a clinical-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal cancers, with eRapa as its core pipeline product.